cyclophosphamide / Generic mfg. - LARVOL DELTA

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. (PubMed, Lancet) - P3 | "BrECADD guided by PET after two cycles is better tolerated and more effective than eBEACOPP in first-line treatment of adult patients with advanced-stage, classical Hodgkin lymphoma."

Journal • Metastases • P3 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. (PubMed, N Engl J Med) - P3 | "Acalabrutinib-venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, NCT03836261.)."

Clinical • IO biomarker • Journal • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Novel Coronavirus Disease • Oncology • Respiratory Diseases • IGH • TP53

First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint CISH is inhibited (AACR 2025) - P1/2 | "CISH KO, neoantigen-reactive TILs were expanded, then infused following non-myeloablative lymphocyte depleting (LD) chemotherapy (cyclophosphamide & fludarabine) followed by high-dose IL-2. We provide the first clinical report of CISH checkpoint targeting via genetically modified T cell therapy, with complete response in a patient with mCRC. Persistence and expansion of unique TCR clonotypes detected in neoantigen responsive TIL was temporally consistent with spikes in CISH edited alleles detected by NGS assay; in the patient with CR, four of the clonotypes exhibiting prolonged persistence greater than one-year post-infusion exhibited significantly reduced or undetectable expression of CISH compared to the total infused TIL population. Given these findings, further investigation of CISH checkpoint inhibition, via gene and cell therapy, and next-generation small molecule drugging modalities, is underway."

Clinical • IO biomarker • Metastases • P1 data • Tumor-infiltrating lymphocyte • Colorectal Cancer • Melanoma • Microsatellite Instability • Oncology • Solid Tumor • MSI

SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma. (ASCO 2025) - P3 | "Following lymphodepletion with cyclophosphamide (500 mg/m2 x 4 days) and fludarabine (30 mg/m2 x 4 days), 1-10x109 IMA203 TCR-T cells will be administered, followed by low-dose IL-2 (1mio IU daily x5 days, twice daily x5 days). Patients in the control arm will receive approved investigator's choice of standard treatment (nivolumab/relatlimab, nivolumab, ipilimumab, pembrolizumab, lifileucel (US), chemotherapy)...Secondary endpoints include OS, ORR, safety and patient-reported outcomes (EORTC QLQ-C30, EQ-5D-5L). The trial will enroll patients in the US and Europe."

Clinical • IO biomarker • Metastases • P3 data • Cutaneous Melanoma • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma • BRAF • HLA-A • PRAME

ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy. (ASCO 2025) - P2 | "Funded by Allogene Therapeutics, Inc Clinical Trial Registration Number: NCT06500273 Background: R-CHOP as 1L therapy for LBCL has a cure rate of ~60%...In Part A (currently enrolling), pts will be randomized to SOC observation or to 1 of 2 treatment arms (cema-cel [120×106 CAR T cells] following 3-day LD with fludarabine [30 mg/m2/day] and cyclophosphamide [300 mg/m2/day] with/without the anti-CD52 monoclonal antibody, ALLO-647 [30 mg/day]).."

Clinical • Minimal residual disease • P2 data • Residual disease • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma. (PubMed, Br J Haematol) - No abstract available

Journal • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. (PubMed, N Engl J Med) - P3 | "The combination of post-transplantation cyclophosphamide and a calcineurin inhibitor led to longer GVHD-free, relapse-free survival than standard prophylaxis after transplantation from a matched related donor with either reduced-intensity or myeloablative conditioning in patients with blood cancers. (Funded by the Australian Government Medical Research Future Fund and others; ALLG BM12 CAST Australian-New Zealand Clinical Trials Registry number, ACTRN12618000505202.)."

Journal • Acute Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Oncology • Transplantation

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation. (PubMed, J Clin Oncol) - P2 | "PTCy-based GVHD prophylaxis after MMUD HSCT with PBSC grafts results in favorable 1 year OS. Using MMUDs expands donor availability to all patients regardless of ancestry (ACCESS; ClinicalTrials.gov identifier: NCT04904588)."

Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Oncology • Transplantation

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma. (PubMed, J Hepatol) - P1 | "Lymphodepletion chemotherapy followed by ADP-A2AFP TCR T-cell therapy showed a manageable safety profile and preliminary indications of antitumor activity in these previously treated patients."

Journal • P1 data • Gastric Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • Transplantation • AFP • CD8

Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials. (PubMed, Transplant Cell Ther) - "Co-administration of a GSI with BCMA CAR-T therapy was associated with improved survival in BCMA-naïve RRMM patients, particularly those with low baseline tumor BCMA levels. These findings suggest GSI modulation of BCMA surface expression may enhance CAR-T efficacy in select patients and support further prospective investigation."

IO biomarker • Journal • P1 data • Hematological Malignancies • Multiple Myeloma • Oncology

DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC) (ESMO 2025) - P3 | "We report neoadjuvant T-DXd or T-DXd-THP vs dose-dense doxorubicin + cyclophosphamide (ddAC)-THP in a phase 3, multicenter, open-label, randomized study. Table: 291O T-DXd-THP ddAC-THP Full analysis set, n 321 320 pCR rate, %* 67.3 56.3 ΔpCR vs ddAC-THP, % (95% CI; P value) † 11.2 (4.0, 18.3; 0.003) − EFS hazard ratio (95% CI) ‡ 0.56 (0.26, 1.17) − Safety analysis set, n 320 312 Any SAE, n (%) 34 (10.6) 63 (20.2) Any AE leading to, n (%) Dose reduction 58 (18.1) 60 (19.2) Dose interruption 121 (37.8) 170 (54.5) Drug discontinuation 45 (14.1) 31 (9.9) Death 2 (0.6) 2 (0.6) Drug-related adjudicated ILD / pneumonitis, n (%) 14 (4.4) 16 (5.1) Grade ≥3 2 (0.6) 6 (1.9) 5 1 (0.3) 1 (0.3) Left ventricular dysfunction, n (%) 6 (1.9) 28 (9.0) Grade ≥3 1 (0.3) 7 (2.2) *By blinded central review † Stratified Miettinen & Nurminen method; P value crossed the 0.03 prespecified boundary ‡ 4.5% maturity Conclusions Neoadjuvant T-DXd-THP demonstrated a clinically meaningful and..."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Low dose pembrolizumab in addition to neoadjuvant anthracycline and taxane in triple-negative breast cancer: A randomized controlled trial (ESMO 2025) - "Patients with untreated stage II-III TNBC without access to standard dose pembrolizumab (SDPm) were randomized (1:1) to receive neoadjuvant dose-dense chemotherapy (4 cycles of doxorubicin and cyclophosphamide followed by 4 cycles of paclitaxel) with or without 50 mg LDPm administered every 6 weeks for 3 cycles. Conclusions The absolute benefit with LDPm appears numerically comparable to that observed with SDPm in the KN522 trial. Therefore, in resource-constrained settings where SDPm is inaccessible, a low-dose alternative strategy may provide a viable treatment option in patients with TNBC."

Clinical • Late-breaking abstract • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm,phase 1 study(fumanba-2) (ASH 2025) - P1 | "Pts would undergo 4 cycles ofinduction chemotherapy based on one of three regimens: Bortezomib-Lenalidomide-Dexamethasone,Bortezomib-Cyclophosphamide-Dexamethasone, or Bortezomib-Adriamycin-Dexamethasone...After lymphodepletion with Fludarabine-Cyclophosphamide, pts received a single infusion of Eque-cel at the dose of 1.0 x 106 CAR-T cells/Kg.Primary endpoint was the proportion of minimal residual disease (MRD)-negative (MRD−; sensitivity <10-5) and progression-free survival (PFS)...Soluble BCMA was cleared within 1 month post infusion in 81.25% (13/16) of pts.Secretion of inflammatory cytokines was also observed, with median peak levels of 58.59 pg/mL (range:9.12-3017.83 pg/mL) for IL-6, 44.30 mg/L (range: 3.66-117.30 mg/L) for CRP, and 553.35 ng/mL (range:68.10-2349.00 ng/mL) for ferritin.In conclusion, the current data suggest that Eque-cel could be a promising and effective treatment optionfor high-risk NDMM pts following induction therapy. However, longer..."

CAR T-Cell Therapy • Clinical • P1 data • CNS Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Multiple Myeloma • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Transplantation • IL6

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma (ASH 2025) - P1/2, P3 | "Introduction: The CARTITUDE-4 study (NCT04181827), which enrolled patients with lenalidomide-refractory multiple myeloma (MM) after 1–3 prior lines of therapy (pLOT), demonstrated a significantbenefit of ciltacabtagene autoleucel (cilta-cel) over established triplet regimens...Here, we report outcomes inpatients with standard-risk cytogenetics from the intent-to-treat and as-treated populations inCARTITUDE-4. In CARTITUDE-4, patients randomized to the cilta-cel arm underwent apheresis and bridgingtreatment with either pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab,pomalidomide, and dexamethasone (DPd), followed by lymphodepletion therapy with cyclophosphamideand fludarabine, and then a single cilta-cel infusion... The PFS rate at 2.5 years for patients with standard-risk RRMM was higher in CARTITUDE-4compared with CARTITUDE-1, supporting the use of cilta-cel as early as second line in the treatmentcourse. In CARTITUDE-4 (as-treated..."

Hematological Malignancies • Multiple Myeloma

Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients (ASH 2025) - "RADAR HRv4 pathway is the largest analysis of ultra-high risk (double hit) patients reportedto date. All participants meet the new IMS/IMWG HR criteria. Isa-VRDc induction, followed by Isa-VRDconsolidation post-ASCT and IsaR maintenance met the primary endpoint, with the study crossing theGreen design threshold, with 88% (59/67) alive and progression-free at 18 months."

Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Transplantation

OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study (ASH 2025) - P1 | "We report preliminary data from an ongoing phase I, first-in-human, dose-escalation and dose-expansion study (NCT06644118). Patients with R/R MM who had received ≥3 prior lines of therapies underwent standardlymphodepletion (fludarabine/cyclophosphamide) followed by a single OL-101 infusion at 3 dose levels(DL1: 1.0×106, DL2: 2.0×106, DL3: 1.5×106 cells/kg)...At the 2.0×106 cells/kg dose level, 1 of 6 patientsexperienced a DLT, manifested as grade 4 CRS with onset on Day 3 post-infusion, which resolved by Day17 following treatment with tocilizumab, steroids, plasma exchange and other supportive care... OL-101, a novel bispecific BCMA/GPRC5D VHH CAR-T, demonstrates promising efficacy (100%ORR, 100% MRD negativity) and manageable safety (CRS manageable, no ICANS) in heavily pretreated,triple-class exposed R/R MM patients, with no new safety signals identified than those with previouslyreported BCMA or GPRC5D targeting CAR-T cells. Notably,..."

IO biomarker • P1 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Plasmacytoma • Thrombocytopenia • GPRC5D

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma (ASH 2025) - "Patients in the cilta-cel arm underwent apheresis, received at least 1 cycle of bridging therapy(investigator's choice) with either pomalidomide, bortezomib, and dexamethasone (PVd) ordaratumumab, pomalidomide, and dexamethasone (DPd), lymphodepletion (cyclophosphamide andfludarabine), and then a single cilta-cel infusion 5–7 days after the start of lymphodepletion. In patients from CARTITUDE-4, better response to bridging therapy correlated with longerPFS and OS. No MNTs were observed in patients who achieved PR or greater following bridging therapy.Patients with poorer responses to bridging therapy were more likely to develop fatal infections,prolonged thrombocytopenia and neutropenia, and had higher rates of non-relapse mortality followingcilta-cel infusion. These data emphasize the importance of optimizing bridging therapy for diseasecontrol prior to receiving cilta-cel."

Clinical • P3 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia

Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia (ASH 2025) - P2 | "Patients received huCART19 at a dose of 5x106 CAR T cells/kg (maximum 2.5x108) afterlymphodepletion (LD) with fludarabine and cyclophosphamide...Prior therapy included HSCT in 21%, blinatumomab in 21% and inotuzumab in 15%.The CAR-naïve cohort (n=52) included 25 with first early BM relapse within 36m of diagnosis (12 25% blasts, 25/52 (48%) <0.01%...There was 1 death prior to day 28, due to gastrointestinal hemorrhageon day 2 in the setting of progressive ALL and Gr 2 CRS. CAR neurotoxicity was reported in 14/52 (27%, 2Gr 3, 2 Gr 4) CAR-naïve patients and 7/48 (15%, 1 Gr 3, 1 Gr 4) CAR-exposed, with 1 case of Gr 3 cerebraledema, fully recovered, and 1 case of ongoing myelopathy.ConclusionsHuCART19 produced durable remissions in high risk r/r B-ALL and demonstrated efficacy as salvagetherapy for those with poor response to prior CAR therapy, comparing favorably to historical outcomes inthis extremely high risk group."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia

CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission (ASH 2025) - P1 | "2022), administered following LD with fludarabine and cyclophosphamide.Pts are followed for toxicity and minimal residual disease (MRD) relapse by flow cytometry (FC) andclonoSEQ (if feasible) every 3 months for 2 years...Six pts had Ph+, 5 hadnot otherwise specified (NOS), 2 had hypodiploidy/TP53m, 2 had CRLF2-rearranged Ph-like, 1 each hadKMT2Ar, EP300::ZNF384, and TCF3::PBX1; 15 (83%) and 2 (11%) pts received blinatumomab andinotuzumab as part of initial therapy, respectively...A second pt (75 yrs old; received induction with hyper CVAD +inotuzumab) developed therapy-related myelodysplastic syndrome 18 months post CAR-T... The use of CAR-T in older adults with B-ALL in MRD- CR1 is safe, with the only encounteredtoxicity of G1 CRS, which was manageable. CAR-T cells expanded in the blood and CSF despite the lowantigen setting. We observed preliminary durable MRD- CR with preserved function and cognition on day100 post CAR-T."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • CRLF2 • EP300 • KMT2A • PBX1 • TCF3 • ZNF384

Incorporation of 8Gy total body irradiation into reduced intensity conditioning does not improve allogeneic transplant outcomes for high-risk adult acute lymphoblastic leukemia: Results from the randomised prospective phase 2 UK multicentre ALL-RIC impact study (ASH 2025) - "We therefore performed a prospective,randomised comparison of the UK FMA RIC regimen with a cyclophosphamide plus 8Gy TBI RIC protocol(Cy/8TBI), with the goal of improving OS in high-risk adult ALL.MethodsThe FMA RIC regimen (fludarabine 30mg/m2 IV for 5d; melphalan 140mg/m2 IV single dose; alemtuzumab 30mg IV D-1 for sibling donor/20mg IV D-2 & -1 for unrelated donor) was compared tocyclophosphamide 50mg/kg for 2d plus 8Gy TBI (4# over 2d) and alemtuzumab (dosed as per FMA).Intrathecal prophylaxis was given for 2y post-SCT. However, incorporation of 8Gy TBI into a RIC protocol designed for older adults was welltolerated, with no increases in acute or chronic GvHD, and no additional infectious or extramedullarytoxicity.These data highlight the importance of performing randomised trials of innovative conditioningregimens, if outcomes for older patients receiving allo-SCT for ALL are to be improved. Importantly theALL-RIC trial showcases feasibility and patient..."

Clinical • P2 data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • T Acute Lymphoblastic Leukemia • Transplantation • KMT2A

Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM) (ASH 2025) - P2 | "Beside Rituximab-Bendamustine, the Dexamethasone, Rituximab and Cyclophospamide (DRC) regimen isstill one of the most frequently used first-line treatments for patients with Waldenström'sMacroglobulinemia (WM). The currently running prospectively randomized VIWA-1trial (NCT05099471) of the ECWM compares 6 cycles of DRC to Venetoclax/Ritxuximab given for 12months in treatment naive WM. It will help to understand to which extent first-line targeted treatmentscan outcompete Rituximab/chemotherapy when applied as fixed-duration treatment in WM."

Clinical • Lymphoma • Lymphoplasmacytic Lymphoma • Waldenstrom Macroglobulinemia • CXCR4 • MYD88

Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T (ASH 2025) - P1 | "Pts receivedlymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (750 mg/m²/day) for 3 days(Aug/Cy), followed by azer-cel infusion (500 × 10⁶ cells) on Day 0 and SC low-dose IL-2 (1 million IU daily)on Days 1-14. Azer-cel followed by low-dose SC IL-2 demonstrates encouraging clinical activity in pts withLBCL who relapsed after prior autologous CD19 CAR T therapy, which remains a significant unmetmedical need. Promising response and CR rates, early evidence of durability, robust CAR T-cell expansionand a manageable safety profile support further investigation of this regimen as a potential treatmentoption for these patients."

Clinical • Combination therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Graft versus Host Disease • Hematological Malignancies • High-grade B-cell lymphoma • Immunology • Indolent Lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer (SABCS 2025) - P2 | "Patients subsequently received pembrolizumab with 12 weeks of paclitaxel, followed by 4 cycles of adriamycin-cyclophosphamide (q2wk or q3wk) with pembrolizumab (200 mg q3 wks or 400 mg q6 wks). The addition of 24Gy preop RT to aPD1 significantly increased tumor TCI in HR+/HER2- early-stage BC. Non-irradiated nodal response rates were promising despite over one-third of the study population with grade 1/2 tumors and high disease burden, laying the foundation for a future randomized trial comparing the efficacy of this novel approach against standard of care for node-positive HR+/HER2- BC."

Clinical • IO biomarker • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • CD8 • HER-2 • PGR

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study (ASH 2025) - "In the GHSG HD21 trial for advanced-stage classic Hodgkin lymphoma (AS-cHL), patients received polychemotherapy regimens (eBEACOPP[bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone] orBrECADD [brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, anddexamethasone]) with a risk to develop febrile neutropenia (FN) and/or infections. This comprehensive analysis of the HD21 trial demonstrates the efficacy of ABP and peg G-CSF in thetreatment of AS-cHL in preventing FN and higher-grade infections. This effect is most pronounced in thefirst cycle and in patients receiving BrECADD. Based on these results, we recommend the use of ABPduring the first cycle of the BrECADD regimen, at least."

Clinical • Metastases • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia

CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL (ASH 2025) - P2 | "Introduction: The 4-year disease-free survival (DFS) of children with first isolated central nervous system(iCNS) relapse treated on the most recent Children's Oncology Group AALL1331 randomized phase 3 trialwas extremely poor at 24%, and the addition of blinatumomab failed to improve outcomes...We conducted a Phase 2 trial ofCTL019, the construct that was FDA approved as tisagenlecleucel, for this population (NCT04276870). Patients 0-29 years (y) of age with CNS relapse of B-ALL without receipt of cXRT for this relapsewere lymphodepleted with fludarabine/cyclophosphamide prior to infusion with 5x106 CART19 cells/kg...In this Phase 2 trial, CART19 achieved an 85% 2‑year EFS in CNS‑relapsed B‑ALL with 88% (38/43) ofpatients avoiding toxic cranial radiation, the SOC for CNS relapse for decades. While longer follow-up isneeded, the 4y EFS of 71% and OS of 93% in the 14 patients with 4+ years of follow-up is promising and issuperior to the outcomes on AALL1331...."

CAR T-Cell Therapy • Clinical • CNS Disorders • Epilepsy • Inflammation • Pediatrics